4D Molecular Therapeutics (FDMT) Profit After Tax Growth (3y) (2023 - 2026)
4D Molecular Therapeutics (FDMT) Profit After Tax Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | 9.53% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -27.65% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 70.25% |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 47.10% |
| 10 | 4D Molecular Therapeutics | 713.32 Mn | 322.42 Mn | - | -33.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.84% |
| Dec 31, 2025 | 39.39% |
| Sep 30, 2025 | -30.33% |
| Jun 30, 2025 | -24.85% |
| Mar 31, 2025 | -22.12% |
| Dec 31, 2024 | -25.58% |
| Sep 30, 2024 | -25.39% |
| Jun 30, 2024 | -66.38% |
| Mar 31, 2024 | -25.46% |
| Dec 31, 2023 | -16.25% |
| Sep 30, 2023 | -9.40% |
| Jun 30, 2023 | -25.03% |
| Mar 31, 2023 | -29.65% |